DFE Pharma expands its inhalation portfolio with the launch of Lactohale 400
Being a leader in Dry Powder Inhalation, DFE Pharma further expands its broad excipient portfolio of inhalation grade lactose
<br />
Lactohale400 | 05/07/2022 | By Sudeep Soparkar | 576
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy